Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bohai Pharma Appoints New Management Team
Bohai Pharma has also appointed Ning Tang, Hongbin Shan and Chunhong Jiang as vice president of operations, vice president of sales and marketing and secretary and treasurer, respectively,
Bohai Pharma has also appointed Ning Tang, Hongbin Shan and Chunhong Jiang as vice president of operations, vice president of sales and marketing and secretary and treasurer, respectively,
Boston Scientific said that the Taxus Element Stent System is the company’s third-generation drug-eluting stent (DES) technology and incorporates a platinum chromium alloy with an innovative stent design
FDA granted approval to market Oxaliplatin Injection in two dosage strengths to Fresenius Kabi Oncology. Oxaliplatin injection is therapeutically equivalent to Eloxatin, which is invented and marketed by
Bristol-Myers Squibb and Pfizer said that the Averroes study is expected to be stopped early because a predefined interim analysis by an independent Data Monitoring Committee (DMC) showed
Merge Healthcare claimed that the new CIMS solution is the first open platform in the industry that allows organisations involved in clinical trials to transparently execute the imaging
As per the terms of the agreement, Danone is expected to pay an amount of approximately $62m in cash to MNI’s shareholders for the acquisition of 100% of
WaferGen said that the first panel, SmartChip Human MicroRNA Panel, provides a comprehensive human microRNA profile of more than 800 microRNAs on a single SmartChip and usefull with
NexMed management has been advised that Health Canada is continuing to review its response for acceptance, and the company expects to hear from the agency within the next
Cell Therapeutics’ PIX301 trial analyses demonstrated that patients who achieved a complete response (CR)/unconfirmed complete response (CRu) to Pixuvri had up to a 63% probability of being alive
Benlysta is being developed by GlaxoSmithKline (GSK) and HGS under a co-development and commercialisation agreement entered into in 2006. Benlysta is an investigational human monoclonal antibody drug. Both